Related Experiment Video
Updated: Dec 5, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions
Marica Iommi1, Simona Rosa1, Michele Fusaroli2
1Department of Biomedical and Neuromotor Sciences-Hygiene and Biostatistics Unit, University of Bologna, Bologna, Italy.
Background:
Estimating the morbidity of a population is strategic for health systems to improve healthcare. In recent years administrative databases have been increasingly used to predict health outcomes. In 1992, Von Korff proposed a Chronic Disease Score (CDS) to predict 1-year mortality by only using drug prescription data. Because pharmacotherapy underwent many changes over the last 3 decades, the original version of the CDS has limitations. The aim of this paper is to report on the development of the modified version of the CDS.
Methods:
The modified CDS (M-CDS) was developed using 33 variables (from drug prescriptions within two-year before 01/01/2018) to predict one-year mortality in Bologna residents aged ≥50 years. The population was split into training and testing sets for internal validation. Score weights were estimated in the training set using Cox regression model with LASSO procedure for variables selection. The external validation was carried out on the Imola population. The predictive ability of M-CDS was assessed using ROC analysis and compared with that of the Charlson Comorbidity Index (CCI), that is based on hospital data only, and of the Multisource Comorbidity Score (MCS), which uses hospital and pharmaceutical data.
Results:
The predictive ability of M-CDS was similar in the training and testing sets (AUC 95% CI: training [0.760-0.770] vs. testing [0.750-0.772]) and in the external population (Imola AUC 95% CI [0.756-0.781]). M-CDS was significantly better than CCI (M-CDS AUC = 0.761, 95% CI [0.750-0.772] vs. CCI-AUC = 0.696, 95% CI [0.681-0.711]). No significant difference was found between M-CDS and MCS (MCS AUC = 0.762, 95% CI [0.749-0.775]).
Conclusions:
M-CDS, using only drug prescriptions, has a better performance than the CCI score in predicting 1-year mortality, and is not inferior to the multisource comorbidity score. M-CDS can be used for population risk stratification, for risk-adjustment in association studies and to predict the individual risk of death.
Related Concept Videos
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Drug Dosing: Geriatric Patients
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

